{"id":"NCT00460655","sponsor":"GlaxoSmithKline","briefTitle":"Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity","officialTitle":"A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Lower Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-04-16","resultsPosted":"2010-01-26","lastUpdate":"2010-09-08"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Post-Stroke Spasticity","Cerebrovascular Accident"],"interventions":[{"type":"DRUG","name":"GSK1358820","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BTX","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to confirm the superior efficacy of GSK1358820 over placebo in patients with equinus deformity associated with post-stroke lower limb spasticity using the Modified Ashworth Scale (MAS) ankle score.","primaryOutcome":{"measure":"Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Ankle Score to the End of the DB Phase (Week 12)","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"BTX 300U","deltaMin":-8.513,"sd":6.6904},{"arm":"Placebo","deltaMin":-5.085,"sd":6.6496}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":22},"locations":{"siteCount":20,"countries":["Japan"]},"refs":{"pmids":["20358216"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":58},"commonTop":["Nasopharyngitis","Contusion","Eczema","Myalgia","Injection site pain"]}}